Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the acceptance range with which two
Symbicort Turbohaler batches could be declared bioequivalent in a bioequivalence setting. The
secondary objective is to compare pharmacokinetic parameters of the reference product batches
and Budesonide/formoterol Easyhaler.
Phase:
Phase 1
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate